ValuEngine Upgrades Viking Therapeutics, Inc. (VKTX) to “Sell”

ValuEngine upgraded shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) from a strong sell rating to a sell rating in a research note released on Thursday morning.

A number of other research analysts have also recently commented on VKTX. Maxim Group restated a buy rating and set a $5.00 price target on shares of Viking Therapeutics in a research note on Thursday, May 11th. HC Wainwright restated a buy rating and set a $7.00 price target (up from $5.00) on shares of Viking Therapeutics in a research note on Monday, July 17th.

Viking Therapeutics (NASDAQ:VKTX) opened at 1.15 on Thursday. Viking Therapeutics has a one year low of $0.88 and a one year high of $1.70. The stock has a 50 day moving average price of $1.05 and a 200-day moving average price of $1.22. The stock’s market capitalization is $31.85 million.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.02. Analysts anticipate that Viking Therapeutics will post ($0.82) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “ValuEngine Upgrades Viking Therapeutics, Inc. (VKTX) to “Sell”” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/09/11/valuengine-upgrades-viking-therapeutics-inc-vktx-to-sell.html.

An institutional investor recently raised its position in Viking Therapeutics stock. Renaissance Technologies LLC increased its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 62.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 265,800 shares of the biotechnology company’s stock after acquiring an additional 102,600 shares during the period. Renaissance Technologies LLC owned approximately 1.12% of Viking Therapeutics worth $388,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.67% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply